BioLife Solutions inks multi‑year Qkine deal to enable closed‑system CGT workflows

BioLife secures multi‑year Qkine distribution, targets closed‑system CGT workflows

BioLife Solutions is signing a multi‑year agreement to distribute Qkine Limited’s cytokine and growth factor products for cell and gene therapy (CGT) manufacturing, expanding its portfolio of bioproduction tools. Under the deal BioLife receives exclusive worldwide distribution rights to select Qkine products for the CGT market and non‑exclusive rights to others, reflecting a long‑term commercial commitment between the two companies. The arrangement positions BioLife to add biologically active media components to its existing cell culture supplement offerings.

The companies are also launching a joint process development and validation program to enable Qkine to package certain products using BioLife’s proprietary CellSeal® Connect vial system. The CellSeal Connect system is designed for incorporation into closed and automated CGT workflows, aiming to simplify integration into bioprocess operations and reduce contamination risk during transfer and handling. BioLife says the packaging collaboration is intended to support scaled, GMP‑compatible supply chains for cytokines used in therapeutic manufacture.

Executives frame the pact as strategically complementary: BioLife’s chairman and CEO Roderick de Greef says the relationship with Qkine, described as a leader in the fast‑growing cytokines market, aligns with BioLife’s stated strategy to expand into biologically active media components as attractive, fast‑growing adjacent categories. Qkine CEO Dr. Robert Scoffin says combining Qkine’s high‑purity cytokine innovation with BioLife’s market reach and customer relationships aims to deliver greater customer value and advance development and manufacture of next‑generation cell and gene therapies.

Market context for cytokines and CGT manufacturing

Cytokines and growth factors play a central role in regulating cell growth, activation and performance in CGT manufacturing, and demand for high‑quality, scalable reagents is rising as more therapies enter clinical and commercial production. Third‑party research referenced by the companies estimates the global cytokines market at roughly $500 million annually and growing at a mid‑teens compound annual rate toward about $1 billion by 2030, underscoring commercial opportunity for distribution and integrated packaging solutions.

Qkine’s specialization and commercial scope

Qkine, headquartered in Cambridge, England, focuses on producing high‑purity, bioactive growth factors and cytokines to support stem cell and regenerative medicine research, clinical translation and commercial‑scale manufacturing. The partnership leverages Qkine’s product development with BioLife’s distribution footprint and packaging technology to target bioprocess customers in the evolving CGT supply chain.